Cargando…
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associate...
Autores principales: | ACHTEN, Roselie E., VAN LUIJK, Chantal M., VAN DER RIJST, Lisa P., BAKKER, Daphne S., SPEKHORST, Lotte S., ZUITHOFF, Nicolaas P. A., SCHUTTELAAR, Marie L. A., ROMEIJN, Geertruida L. E., VOORBERG, Angelique N., KAMSTEEG, Marijke, HAECK, Inge M., DE GRAAF, Marlies, THIJS, Judith L., DE BOER, Joke H., DE BRUIN-WELLER, Marjolein S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558326/ https://www.ncbi.nlm.nih.gov/pubmed/35098318 http://dx.doi.org/10.2340/actadv.v102.1128 |
Ejemplares similares
-
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023) -
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023) -
The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
por: Voorberg, Angelique N., et al.
Publicado: (2022) -
Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019) -
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
por: Kamphuis, Esmé, et al.
Publicado: (2022)